Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03972709 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 372
- Enrollment target
NCT03972709 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 372 participants.
The verdict
NCT03972709, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 372 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab (FHTR2163) injections.
Interventions
- DRUG Sham Control
- DRUG Galegenimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2022-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03972709
The ClinicalTrials.gov registry entry for NCT03972709 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Control is the first listed.
NCT03972709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03972709 about?
NCT03972709 is a clinical study titled "A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)". This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) com...
What is the current status of trial NCT03972709?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 372 participants. The study started on 2019-06-03. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT03972709?
The interventions under investigation include: Sham Control (DRUG), Galegenimab (DRUG).
Who is sponsoring clinical trial NCT03972709?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.